CN116157387A - 异喹啉化合物及其在治疗AhR失衡中的用途 - Google Patents

异喹啉化合物及其在治疗AhR失衡中的用途 Download PDF

Info

Publication number
CN116157387A
CN116157387A CN202180060054.5A CN202180060054A CN116157387A CN 116157387 A CN116157387 A CN 116157387A CN 202180060054 A CN202180060054 A CN 202180060054A CN 116157387 A CN116157387 A CN 116157387A
Authority
CN
China
Prior art keywords
optionally substituted
compound
alkyl
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180060054.5A
Other languages
English (en)
Chinese (zh)
Inventor
戴维·H·德鲁里
查纳·K·杰亚威克里姆
卡若林·瑟伦斯奇
苏珊·H·史密斯
瑞安·保罗·特朗普
卡罗·威尔士
替莫瑟·威尔逊
张存宇
威廉姆·祖尔彻
艾力逊·艾克斯特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Demawan Science Co ltd
Original Assignee
Demawan Science Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Demawan Science Co ltd filed Critical Demawan Science Co ltd
Publication of CN116157387A publication Critical patent/CN116157387A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
CN202180060054.5A 2020-07-16 2021-05-27 异喹啉化合物及其在治疗AhR失衡中的用途 Pending CN116157387A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063052574P 2020-07-16 2020-07-16
US202063052561P 2020-07-16 2020-07-16
US63/052,574 2020-07-16
US63/052,561 2020-07-16
PCT/US2021/034599 WO2022015423A1 (en) 2020-07-16 2021-05-27 ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE

Publications (1)

Publication Number Publication Date
CN116157387A true CN116157387A (zh) 2023-05-23

Family

ID=79293345

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180060054.5A Pending CN116157387A (zh) 2020-07-16 2021-05-27 异喹啉化合物及其在治疗AhR失衡中的用途

Country Status (10)

Country Link
US (5) US11267788B2 (https=)
EP (1) EP4185566A4 (https=)
JP (1) JP2023533855A (https=)
KR (1) KR20230041021A (https=)
CN (1) CN116157387A (https=)
AU (1) AU2021308209A1 (https=)
CA (1) CA3185793A1 (https=)
IL (1) IL299756A (https=)
MX (1) MX2023000263A (https=)
WO (1) WO2022015423A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117229208A (zh) * 2023-11-13 2023-12-15 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
WO2025082312A1 (zh) * 2023-10-18 2025-04-24 德明药泰生物技术（深圳）有限公司 芳香烃受体调节剂类化合物及其制备方法和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533855A (ja) 2020-07-16 2023-08-04 ダーマヴァント サイエンシーズ ゲーエムベーハー イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用
WO2024020170A1 (en) * 2022-07-21 2024-01-25 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. Aryl hydrocarbon receptor agonist prodrugs and methods of use thereof
US20260069585A1 (en) * 2022-08-30 2026-03-12 Dermavant Sciences GmbH ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
WO2024152993A1 (zh) * 2023-01-17 2024-07-25 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
WO2026083733A1 (ja) * 2024-10-18 2026-04-23 株式会社ヤクルト本社 試験方法、ゲル状組成物、及び試験装置

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020013460A1 (en) * 1997-10-02 2002-01-31 Eisai Co., Ltd Condensed pyridine compound
US20030232877A1 (en) * 2001-12-19 2003-12-18 Sikorski James A. 1,3-Bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
CN1596240A (zh) * 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
US20130116278A1 (en) * 2010-06-09 2013-05-09 Edmond J. LaVoie Antimicrobial agents
CN104837829A (zh) * 2012-09-07 2015-08-12 癌症研究科技有限公司 抑制剂化合物
WO2018178001A1 (de) * 2017-03-29 2018-10-04 Merck Patent Gmbh Metallkomplexe
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN116947799A (zh) * 2023-03-08 2023-10-27 上海泽德曼医药科技有限公司 酚类化合物、其制备方法及其在医药上的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018123A2 (en) 1991-04-10 1992-10-29 Octamer, Inc. A method for inhibition of retroviral replication
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
HRP20040102A2 (en) 2001-07-09 2004-10-31 Combinatorx Combinations for the treatment of inflammatory disorders
JPWO2005063222A1 (ja) 2003-12-26 2007-07-19 協和醗酵工業株式会社 Ｈｓｐ９０ファミリー蛋白質阻害剤
WO2006058201A2 (en) 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
GB0704718D0 (en) 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
EP2014651A1 (en) 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
JP5439127B2 (ja) 2009-11-13 2014-03-12 株式会社さいわいメディカル 乾癬又はアトピー性皮膚炎治療剤
AU2013361314A1 (en) 2012-12-20 2015-07-02 Aldeyra Therapeutics, Inc. Peri-carbinols
GB201304041D0 (en) 2013-03-06 2013-04-17 Water Jel Europ Llp Treatment and prophylaxis of radiation dermatitis
US10626094B2 (en) 2014-10-14 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
US11548867B2 (en) * 2017-07-19 2023-01-10 Idea Ya Biosciences, Inc. Amido compounds as AhR modulators
EP3752512B1 (de) * 2018-02-13 2023-03-01 Merck Patent GmbH Metallkomplexe
TWI828664B (zh) 2018-03-19 2024-01-11 愛爾蘭商Ｕｄｃ愛爾蘭責任有限公司 金屬錯合物
JP2023533855A (ja) 2020-07-16 2023-08-04 ダーマヴァント サイエンシーズ ゲーエムベーハー イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020013460A1 (en) * 1997-10-02 2002-01-31 Eisai Co., Ltd Condensed pyridine compound
US20030232877A1 (en) * 2001-12-19 2003-12-18 Sikorski James A. 1,3-Bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
CN1596240A (zh) * 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
US20130116278A1 (en) * 2010-06-09 2013-05-09 Edmond J. LaVoie Antimicrobial agents
CN104837829A (zh) * 2012-09-07 2015-08-12 癌症研究科技有限公司 抑制剂化合物
WO2018178001A1 (de) * 2017-03-29 2018-10-04 Merck Patent Gmbh Metallkomplexe
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN116947799A (zh) * 2023-03-08 2023-10-27 上海泽德曼医药科技有限公司 酚类化合物、其制备方法及其在医药上的应用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALEXIA N. KIM等: "Iridium-Catalyzed Enantioselective and Diastereoselective Hydrogenation of 1, 3-Disubstituted Isoquinolines", ACS CATAL., vol. 10, 10 February 2020 (2020-02-10), pages 1 - 302 *
DAULAT BIKRAM KHADKA等: "Design, synthesis, and biological evaluation of 1, 3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY., vol. 143, 7 November 2017 (2017-11-07), pages 200 - 215, XP085306027, DOI: 10.1016/j.ejmech.2017.11.011 *
JOHN J. FITZGERALD等: "Reaction of Benzocyclobutenoxldes with Nitriles: Synthesis of Hypecumine and Other 3-Substituted lsoquinolines", TETRAHEDRON LETTERS, vol. 35, no. 49, 14 October 1994 (1994-10-14), pages 9191 - 9194 *
PAWAN K. MISHRA等: "Harnessing the reactivity of ortho-formyl-arylketones: base-promoted regiospecific synthesis of functionalized isoquinolines", CHEM.COMMUN., vol. 55, no. 57, 21 July 2019 (2019-07-21), pages 8278 - 8281, XP093186033, DOI: 10.1039/C9CC03689J *
QINHUA HUANG等: "Synthesis of Substituted Isoquinolines by Electrophilic Cyclization of Iminoalkynes", J. ORG. CHEM., vol. 67, 24 April 2002 (2002-04-24), pages 3437 - 3444, XP093186154, DOI: 10.1021/jo020020e *
SUHUI YANG等: "Synthesis, in vitro and in vivo evaluation of 3-arylisoquinolinamines as potent antitumor agents", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20, 3 July 2010 (2010-07-03), pages 5277 *
VIRENDRA KUMAR TIWARI等: "One Substrate, Two Modes of C−H Functionalization: A Metal-Controlled Site-Selectivity Switch in C−H Arylation Reactions", ORG.LETT., vol. 19, no. 1, 6 January 2017 (2017-01-06), pages 262 - 265 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025082312A1 (zh) * 2023-10-18 2025-04-24 德明药泰生物技术（深圳）有限公司 芳香烃受体调节剂类化合物及其制备方法和应用
CN117229208A (zh) * 2023-11-13 2023-12-15 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
CN117229208B (zh) * 2023-11-13 2024-02-23 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
US20240208910A1 (en) 2024-06-27
EP4185566A4 (en) 2024-12-04
KR20230041021A (ko) 2023-03-23
US20250282730A1 (en) 2025-09-11
MX2023000263A (es) 2023-03-29
US11827605B2 (en) 2023-11-28
AU2021308209A8 (en) 2023-04-13
IL299756A (en) 2023-03-01
AU2021308209A1 (en) 2023-02-09
US12252471B2 (en) 2025-03-18
CA3185793A1 (en) 2022-01-20
JP2023533855A (ja) 2023-08-04
WO2022015423A1 (en) 2022-01-20
US20220153703A1 (en) 2022-05-19
US11267788B2 (en) 2022-03-08
US11548853B2 (en) 2023-01-10
EP4185566A1 (en) 2023-05-31
US20230124135A1 (en) 2023-04-20
US20220017468A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
CN116157387A (zh) 异喹啉化合物及其在治疗AhR失衡中的用途
JP5735986B2 (ja) 新規抗マラリア剤
EP3130583B1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US10676438B2 (en) KCNQ2-5 channel activator
HUE030081T2 (en) Heterocyclic benzodioxole or benzodioxepine compounds as phosphodiesterase inhibitors
US12234218B2 (en) Heterocyclic compounds as modulators of mGluR7
US11299497B2 (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
US20220298176A1 (en) Heteroaryl plasma kallikrein inhibitors
US20210079012A1 (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
WO2014013182A1 (fr) Derive d'imidazopyridine utiles dans le traitement du diabete
US20260069585A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
JP7624745B2 (ja) Ｔｒｐｖ４受容体リガンド
US20250340537A1 (en) Pharmaceutically active compounds, compositions, and methods for modulating pendrin
KR20210080378A (ko) 비만의 치료
CN109734712A (zh) 芳基或杂芳基取代的吡咯烷酰胺衍生物及其用途
CN117999072A (zh) β肾上腺素能激动剂和其使用方法
JP2025529076A (ja) ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤
US9896415B2 (en) Chalcone derivatives having an anti-allergic activity
HK1175472B (en) New anti-malarial agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination